Executive Privilege: How Giving Trump Special Access To Experimental COVID Treatment Could Backfire
Trump receives Regeneron’s experimental antibody under FDA’s expanded access program, Gilead’s remdesivir and dexamethasone. The president’s treatment choices could influence clinical trials of all COVID-19 medicines and even trial recruitment for other diseases, experts said.
You may also be interested in...
NIH study of monoclonal antibody therapy in combination with Gilead's remdesivir paused for safety reasons.
Coronavirus Update: Praised By Trump, Regeneron Files Antibody Cocktail For Emergency Use Authorization
Trump's praise of the therapy and talk of a 'cure' for COVID-19 has raised concerns about misinformation and pressure on the US FDA once again.
Following last month’s data showing reduced hospitalization risk with single neutralizing antibody therapy, Lilly now has data showing a two-antibody combo reduces COVID-19 viral load significantly.